NO941151L - Linear adhesion inhibitors - Google Patents
Linear adhesion inhibitorsInfo
- Publication number
- NO941151L NO941151L NO941151A NO941151A NO941151L NO 941151 L NO941151 L NO 941151L NO 941151 A NO941151 A NO 941151A NO 941151 A NO941151 A NO 941151A NO 941151 L NO941151 L NO 941151L
- Authority
- NO
- Norway
- Prior art keywords
- gly
- asn
- lys
- asp
- leu
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- FBKUOPULLUJMOC-UHFFFAOYSA-N 2-[[2-(9h-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 FBKUOPULLUJMOC-UHFFFAOYSA-N 0.000 abstract 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical group C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 abstract 1
- XWOBNBRUDDUEEY-UWVGGRQHSA-N Leu-His Chemical group CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XWOBNBRUDDUEEY-UWVGGRQHSA-N 0.000 abstract 1
- LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 abstract 1
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 108010091798 leucylleucine Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Lineære peptider med formel I. hvor X er H, acyl med 1-10 C-atomer, H-Asn, H-Val-Asn, H-Asp-Val-Asn, Fmoc-Gly-Gly, H-Lys-Gly-Gly, H-Lys-Pro, H-Tyr-Gly-Gly, H-Cys-Gly-Gly, H-Cys(Trt)-Gly-Gly, H-Cys-Gly-Gly-Thr-Asp-Val-Asn eller H-Thr-Asp-Val-Asn; A, B og C uav-hengig av hverandre mangler eller er en aminosyrerest valgt fra en gruppe be-stående av Ala, Arg, Asn, Asp, Asp(OR), Cys, Gin, Glu, Gly, His, Ile, Leu, Lys, Lys(Ac), Lys(AcNH), Lys(AcSH), Met, Orn, Phe, 4-Hal-Phe, Pro, Ser, Thr, Trp, Tyr eller Val, idet de nevnte aminosyrerester også kan være derivati-sert; E er Gly, His eller Leu-His; G mangler eller er Asp eller Asn; L mangler eller er Gly, Ile, Leu eller Leu-Leu; Z er NHeller 0H; Hal er F, Cl, Br eller I; og Ac er alkanoyl med 1-10 C-atomer; samt fysiologisk aksep-table salter derav. Forbindelsene virker som integrininhibitorer og kan særlig anvendes til profylakse og be-handling av sykdommer i blodomløpet og til tumorterapi.remstillingen av forbindelsene er beskrevet.Linear peptides of formula I. wherein X is H, acyl having 1-10 C atoms, H-Asn, H-Val-Asn, H-Asp-Val-Asn, Fmoc-Gly-Gly, H-Lys-Gly- Gly, H-Lys-Pro, H-Tyr-Gly-Gly, H-Cys-Gly-Gly, H-Cys (Trt) -Gly-Gly, H-Cys-Gly-Gly-Thr-Asp-Val-Asn or H-Thr-Asp-Val-Asn; A, B and C independently of one another lack or are an amino acid residue selected from a group consisting of Ala, Arg, Asn, Asp, Asp (OR), Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Lys (Ac), Lys (AcNH), Lys (AcSH), Met, Orn, Phe, 4-Hal-Phe, Pro, Ser, Thr, Trp, Tyr or Val, the said amino acid residues may also be derivatives. sert; E is Gly, His or Leu-His; G is missing or is Asp or Asn; L is missing or is Gly, Ile, Leu or Leu-Leu; Z is NH or OH; Hal is F, Cl, Br or I; and Ac is alkanoyl having 1-10 C atoms; and physiologically acceptable salts thereof. The compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of diseases of the bloodstream and for tumor therapy. The preparation of the compounds is described.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4310632A DE4310632A1 (en) | 1993-04-01 | 1993-04-01 | Linear Adhesion Inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO941151D0 NO941151D0 (en) | 1994-03-29 |
| NO941151L true NO941151L (en) | 1994-10-03 |
Family
ID=6484423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO941151A NO941151L (en) | 1993-04-01 | 1994-03-29 | Linear adhesion inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0618225A1 (en) |
| JP (1) | JPH06321988A (en) |
| CN (1) | CN1099040A (en) |
| AU (1) | AU5798494A (en) |
| CA (1) | CA2120302A1 (en) |
| CZ (1) | CZ70394A3 (en) |
| DE (1) | DE4310632A1 (en) |
| HU (1) | HU9400932D0 (en) |
| NO (1) | NO941151L (en) |
| SK (1) | SK38494A3 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| US5874562A (en) * | 1995-06-07 | 1999-02-23 | Progenitor, Inc. | Nucleic acid encoding developmentally-regulated endothelial cell locus-1 |
| US6100423A (en) * | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
| JPH11510814A (en) * | 1995-08-30 | 1999-09-21 | ジー．ディー．サール アンド カンパニー | Meta-guanidine, urea, thiourea or azacyclic aminobenzoic acid derivatives as integrin antagonists |
| ES2247621T3 (en) | 1996-02-15 | 2006-03-01 | Biosense Webster, Inc. | EXCAVATION PROBE. |
| US6443974B1 (en) | 1996-07-28 | 2002-09-03 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
| US6309370B1 (en) | 1998-02-05 | 2001-10-30 | Biosense, Inc. | Intracardiac drug delivery |
| PL350291A1 (en) | 1998-12-23 | 2002-12-02 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| PL363153A1 (en) | 2000-06-16 | 2004-11-15 | Hercules Incorporated | Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| GB0323378D0 (en) | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
| PT1737889E (en) | 2004-10-19 | 2010-12-13 | Lonza Ag | Method for solid phase peptide synthesis |
| EP2187916A2 (en) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of gluten exorphin c as a therapeutic agent |
| US20100190717A1 (en) * | 2007-09-11 | 2010-07-29 | Dorian Bevec | Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| CN106279362B (en) * | 2015-06-23 | 2019-07-12 | 首都医科大学 | Arg-Leu-Val-Cys-Val, synthesis, pharmacological activity and application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049659A (en) * | 1988-02-09 | 1991-09-17 | Dana Farber Cancer Institute | Proteins which induce immunological effector cell activation and chemattraction |
| US5196511A (en) * | 1989-12-01 | 1993-03-23 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
-
1993
- 1993-04-01 DE DE4310632A patent/DE4310632A1/en not_active Withdrawn
-
1994
- 1994-03-21 EP EP94104395A patent/EP0618225A1/en not_active Withdrawn
- 1994-03-23 AU AU57984/94A patent/AU5798494A/en not_active Abandoned
- 1994-03-25 CZ CZ94703A patent/CZ70394A3/en unknown
- 1994-03-29 NO NO941151A patent/NO941151L/en unknown
- 1994-03-30 CA CA002120302A patent/CA2120302A1/en not_active Abandoned
- 1994-03-30 CN CN94104073A patent/CN1099040A/en active Pending
- 1994-03-31 SK SK384-94A patent/SK38494A3/en unknown
- 1994-03-31 JP JP6096828A patent/JPH06321988A/en active Pending
- 1994-03-31 HU HU9400932A patent/HU9400932D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU5798494A (en) | 1994-10-06 |
| CN1099040A (en) | 1995-02-22 |
| EP0618225A1 (en) | 1994-10-05 |
| SK38494A3 (en) | 1995-02-08 |
| CA2120302A1 (en) | 1994-10-02 |
| NO941151D0 (en) | 1994-03-29 |
| CZ70394A3 (en) | 1994-12-15 |
| JPH06321988A (en) | 1994-11-22 |
| DE4310632A1 (en) | 1994-10-06 |
| HU9400932D0 (en) | 1994-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU707094B2 (en) | Analogs of parathyroid hormone | |
| US5955574A (en) | Analogs of parathyroid hormone | |
| US7410948B2 (en) | Analogs of parathyroid hormone | |
| NO941151L (en) | Linear adhesion inhibitors | |
| US6544949B1 (en) | Analogs of parathyroid hormone | |
| US5969095A (en) | Analogs of parathyroid hormone | |
| AP2000001905A0 (en) | Peptide compositions and formulations and use of same. | |
| AU633913B2 (en) | Novel tnf-inhibit proteins and their preparation | |
| AU630132B2 (en) | Anticoagulant peptides | |
| EP0384731A2 (en) | Osteogenic growth polypeptides identified from regenerating bone marrow | |
| ES8701784A1 (en) | V1-vasopressin antagonists. | |
| AU671850B2 (en) | Peptide lung surfactants and therapeutic combinations | |
| CA2102447A1 (en) | Cyclopeptides | |
| YU48997A (en) | Novel biologically active proteins, their pharmaceutical compositions and procedure for obtaining thereof | |
| NO954991L (en) | Trifunctional antithrombin and anti-platelet peptides | |
| EP0234935A3 (en) | Vasopressin compounds | |
| CN1916025B (en) | parathyroid hormone analogs | |
| Chen et al. | Synthesis of new substance P analogues releasing histamine from rat peritoneal mast cells | |
| HK1096976B (en) | Analogs of parathyroid hormone | |
| HK1149275A (en) | Analogs of parathyroid hormone | |
| MY125216A (en) | Peptide compositions and formulations and use of same. | |
| AU2002238532A1 (en) | Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |